MYC and neoplasm: Myc inhibitor 10058-F4 suppressed CIP2A in 80% of CD34+ cells (p = 0.04) and 85% of K562 cells (p = 0.01), preventing Myc/MAX interaction and restoring tumour-suppressor functions in vitro K562 and CD34+ cell lines [29,184].